loratadine has been researched along with Urticaria in 118 studies
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.
Urticaria: A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effects of desloratadine citrate disodium on serum immunological function indices (IgE, C3 and C4), inflammatory factors (IL-4, IL-17 and IL-33), and chemokines (MCP-1, RANTES and Eotaxin) in patients with chronic urticaria." | 9.30 | Effects of Desloratadine Citrate Disodium on Serum Immune Function Indices, Inflammatory Factors and Chemokines in Patients with Chronic Urticaria. ( Wang, J; Yan, X; Zhao, Y, 2019) |
| "The effect of citrate to Desloratadine Citrate Disodium set in the treatment of chronic urticaria in patients with IL4, IL18, and IL23, IL33 levels was investigated." | 9.24 | Clinical observation on the therapeutic effect of desloratadine citrate disodium in the treatment of chronic urticaria and changes in IL4, IL18, IL23 and IL-33 levels before and after treatment. ( Yang, X; Zheng, D, 2017) |
| "Rupatadine is effective and well tolerated in the relief of urticaria symptoms, improving quality of life over 6 weeks in children with CSU." | 9.22 | Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. ( Barkai, L; Izquierdo, I; Maurer, M; Mezei, G; Mitha, E; Potter, P; Santamaría, E, 2016) |
| "Levocetirizine led to a significantly greater decrease in pruritus severity than desloratadine over the first treatment week; mean pruritus severity scores of 1." | 9.14 | Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. ( Finlay, AY; Guillet, G; Hauptmann, P; Jian, AM; Kapp, A; Maurer, M; Potter, PC, 2009) |
| "We sought to assess the effects of 5 and 20 mg of desloratadine and placebo on cold-induced urticarial reactions in patients with ACU." | 9.14 | High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. ( Degener, F; Martus, P; Maurer, M; Siebenhaar, F; Zuberbier, T, 2009) |
| "Eighty tertiary referral patients with chronic urticaria (age range, 19-67 years) were randomized for double-blind treatment with levocetirizine or desloratadine (40/40)." | 9.14 | The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. ( Church, DS; Church, MK; Dimitrov, V; Kraeva, S; Kralimarkova, T; Lazarova, C; Popov, TA; Popova, D; Staevska, M, 2010) |
| "To assess the effect of desloratadine on quality of life (QoL) in chronic idiopathic urticaria (CIU)." | 9.13 | Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. ( Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2008) |
| "Our data show a tendency to suppressive effect of montelukast on flare and itching but not on wheal which is basic for SPT interpretation." | 9.12 | The effect of montelukast (10mg daily) and loratadine (10mg daily) on wheal, flare and itching reactions in skin prick tests. ( Górski, P; Kuna, P; Kupczyk, M; Kupryś, I, 2007) |
| "This study has demonstrated that both desloratadine alone and desloratadine plus montelukast administered once daily yield improvements with respect to the baseline assessment, regarding the suppression of the dermographometer challenge test papule and clinical improvement of urticaria." | 9.12 | Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study. ( Colanardi, MC; Ferrannini, A; Nettis, E; Soccio, AL; Vacca, A, 2006) |
| "Desloratadine treatment was associated with significant improvements compared with placebo in pruritus scores and in the size of the largest wheals as early as day 1." | 9.12 | Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. ( Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2007) |
| "Assess the effect of desloratadine 5 mg once daily on the quality of life of patients suffering of chronic idiopathic urticaria (CIU)." | 9.12 | Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria. ( Boonen, H; De Swerdt, A; Decroix, J; Henrijean, A; Lachapelle, JM; Lecuyer, M; Roquet-Gravy, PP; Speelman, G; Suys, E; Vastesaeger, N, 2006) |
| "The effect of 5 mg desloratadine for 4 days was tested with ice-cubes before and after 4 days of treatment in 12 patients with cold urticaria." | 9.11 | Inhibition of cold urticaria by desloratadine. ( Juhlin, L, 2004) |
| " Both desloratadine alone and desloratadine plus montelukast administered once daily yielded improvements with respect to the baseline assessment as regards pruritus, number of separate episodes, size and number of weals, visual analogue score and patients' quality of life and with respect to the placebo group both in the active treatment period and in the run-out period." | 9.11 | Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. ( Colanardi, MC; Ferrannini, A; Nettis, E; Paradiso, MT, 2004) |
| "Compared with placebo, desloratadine significantly improved the total CIU symptom score as well as pruritus, the number of hives, and the size of the largest hive." | 9.10 | Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. ( Bernstein, D; Finn, A; Guerrero, R; Monroe, E; Patel, P; Ratner, P, 2003) |
| "To compare the clinical efficacy and safety of mizolastine with loratadine and placebo in patients with chronic idiopathic urticaria (CIU)." | 9.09 | Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. ( Dubertret, L; Murrieta Aguttes, M; Tonet, J, 1999) |
| "Desloratadine was superior to placebo in controlling pruritus and total symptoms after the first dose and maintained this superiority to the end of the study." | 9.09 | Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. ( Bronsky, E; Gauger, A; Hein, R; Miller, B; Ring, J, 2001) |
| "To analyze the efficacy and safety of Tripterygium Glycosides Tablets combined with desloratadine as well as desloratadine alone in the treatment of chronic urticaria by Meta-analysis,in order to provide evidence-based reference for clinical treatment." | 9.01 | [Meta-analysis of efficacy and safety of Tripterygium Glycosides Tablets combined with desloratadine in treatment of chronic urticarial]. ( Pang, GX; Qiu, XJ; Shi, YS; Wang, QM, 2019) |
| "Bilastine is an orally administered, second-generation antihistamine used in the symptomatic treatment of seasonal or perennial allergic rhinoconjunctivitis and urticaria." | 8.88 | Bilastine: in allergic rhinitis and urticaria. ( Carter, NJ, 2012) |
| " Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0." | 8.86 | Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010) |
| "To demonstrate the treatment outcomes and dose reduction in desloratadine assessed using the urticarial activity score over 7 consecutive days." | 7.88 | The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria. ( Chaowattanapanit, S; Choonhakarn, C; Julanon, N, 2018) |
| "H1-receptor inhibiting drugs, namely loratadine and cetirizine, were frequently used in treatment of chronic urticaria." | 7.80 | Effects of loratadine and cetirizine on serum levels of neuropeptides in patients with chronic urticaria. ( Başak, PY; Buyukbayram, HI; Erturan, I; Kazanoglu, OO; Vural, H, 2014) |
| " Desloratadine, a non-sedating, second-generation H(1)-receptor antagonist, is an effective and well-tolerated treatment for chronic idiopathic urticaria (CIU)." | 7.75 | Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. ( Augustin, M; Ehrle, S, 2009) |
| "The effects of one week's daily treatment with dexchlorpheniramine (3 + 3 mg x 2) and loratadine (10 mg x 2) on the cutaneous reactions to putative mediators of urticarial reactions were studied in healthy subjects and in patients with chronic urticaria." | 7.68 | Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects. ( Juhlin, L; Pihl-Lundin, I, 1992) |
| " The efficiency and side-effect were evaluated at the end of treatment." | 6.73 | Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria. ( Abdalla, AN; Khalaf, AT; Liu, XM; Sheng, WX; Tan, JQ, 2008) |
| "Treatment with desloratadine caused a relevant reduction of ROS levels and SOD activity (P<0." | 6.72 | Influence of desloratadine on oxidative stress markers in patients with chronic idiopathic urticaria. ( Amoruso, A; Cassano, N; D'Argento, V; Filieri, M; Filotico, R; Raho, G; Vena, GA, 2006) |
| "Loratadine is a new, highly selective, non sedating, H 1-receptor antagonist, without central nervous system activity." | 6.67 | [Effectiveness of loratadine vs. placebo in the treatment of urticaria-angioedema syndrome in patients with food allergy]. ( Biasi, D; Corrocher, R; Cortina, P; Girelli, D; Pacor, ML, 1993) |
| "Loratadine is a new selective peripheral histamine H1-receptor antagonist, that is orally effective, long-acting, and devoid of significant central and autonomic nervous system activity." | 6.67 | Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria. ( Belaich, S; Bruttmann, G; DeGreef, H; Lachapelle, JM; Paul, E; Pedrali, P; Tennstedt, D, 1990) |
| "Loratadine was safe and well tolerated with sedation and dry mouth similar to placebo and significantly less than hydroxyzine." | 6.67 | Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. ( Bernstein, DI; Cuss, F; Danzig, MR; Fox, RW; Garvin, PR; Grabiec, SV; Honsinger, RW; Kalivas, JT; Katz, HI; Monroe, EW, 1992) |
| "Desloratadine displays linear pharmacokinetics after oral administration." | 6.44 | Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. ( DuBuske, L, 2007) |
| "Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist." | 6.43 | Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. ( DuBuske, LM, 2005) |
| "Desloratadine is a novel, potent H1-receptor antagonist with additional inhibitory effects on inflammatory mediators such as cytokines and adhesion molecules." | 6.41 | Desloratadine in the treatment of chronic idiopathic urticaria. ( Gauger, A; Hein, R; Ring, J, 2001) |
| "H1 nonsedating antihistamines, such as desloratadine, are first-line treatment options for chronic spontaneous urticaria (CSU)." | 5.34 | Human H1 receptor (HRH1) gene polymorphism is associated with the severity of side effects after desloratadine treatment in Chinese patients with chronic spontaneous uticaria. ( Chen, W; Chen, X; Li, J; Liu, Z; Peng, C; Su, J; Zhang, W; Zhu, W, 2020) |
| "To determine the effects of desloratadine citrate disodium on serum immunological function indices (IgE, C3 and C4), inflammatory factors (IL-4, IL-17 and IL-33), and chemokines (MCP-1, RANTES and Eotaxin) in patients with chronic urticaria." | 5.30 | Effects of Desloratadine Citrate Disodium on Serum Immune Function Indices, Inflammatory Factors and Chemokines in Patients with Chronic Urticaria. ( Wang, J; Yan, X; Zhao, Y, 2019) |
| "The effect of citrate to Desloratadine Citrate Disodium set in the treatment of chronic urticaria in patients with IL4, IL18, and IL23, IL33 levels was investigated." | 5.24 | Clinical observation on the therapeutic effect of desloratadine citrate disodium in the treatment of chronic urticaria and changes in IL4, IL18, IL23 and IL-33 levels before and after treatment. ( Yang, X; Zheng, D, 2017) |
| "Rupatadine is effective and well tolerated in the relief of urticaria symptoms, improving quality of life over 6 weeks in children with CSU." | 5.22 | Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. ( Barkai, L; Izquierdo, I; Maurer, M; Mezei, G; Mitha, E; Potter, P; Santamaría, E, 2016) |
| "Eighty tertiary referral patients with chronic urticaria (age range, 19-67 years) were randomized for double-blind treatment with levocetirizine or desloratadine (40/40)." | 5.14 | The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. ( Church, DS; Church, MK; Dimitrov, V; Kraeva, S; Kralimarkova, T; Lazarova, C; Popov, TA; Popova, D; Staevska, M, 2010) |
| "Levocetirizine led to a significantly greater decrease in pruritus severity than desloratadine over the first treatment week; mean pruritus severity scores of 1." | 5.14 | Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. ( Finlay, AY; Guillet, G; Hauptmann, P; Jian, AM; Kapp, A; Maurer, M; Potter, PC, 2009) |
| "We sought to assess the effects of 5 and 20 mg of desloratadine and placebo on cold-induced urticarial reactions in patients with ACU." | 5.14 | High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. ( Degener, F; Martus, P; Maurer, M; Siebenhaar, F; Zuberbier, T, 2009) |
| "Nonsedating antihistamines (nsAHs) are recommended as first-line therapeutics for the treatment of mast cell-driven disorders, including allergic rhinitis and urticaria." | 5.14 | Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines. ( dos Santos, RV; Lima, HC; Magerl, M; Mlynek, A, 2009) |
| "To assess the effect of desloratadine on quality of life (QoL) in chronic idiopathic urticaria (CIU)." | 5.13 | Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. ( Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2008) |
| "Our data show a tendency to suppressive effect of montelukast on flare and itching but not on wheal which is basic for SPT interpretation." | 5.12 | The effect of montelukast (10mg daily) and loratadine (10mg daily) on wheal, flare and itching reactions in skin prick tests. ( Górski, P; Kuna, P; Kupczyk, M; Kupryś, I, 2007) |
| "Assess the effect of desloratadine 5 mg once daily on the quality of life of patients suffering of chronic idiopathic urticaria (CIU)." | 5.12 | Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria. ( Boonen, H; De Swerdt, A; Decroix, J; Henrijean, A; Lachapelle, JM; Lecuyer, M; Roquet-Gravy, PP; Speelman, G; Suys, E; Vastesaeger, N, 2006) |
| "This study has demonstrated that both desloratadine alone and desloratadine plus montelukast administered once daily yield improvements with respect to the baseline assessment, regarding the suppression of the dermographometer challenge test papule and clinical improvement of urticaria." | 5.12 | Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study. ( Colanardi, MC; Ferrannini, A; Nettis, E; Soccio, AL; Vacca, A, 2006) |
| "Desloratadine treatment was associated with significant improvements compared with placebo in pruritus scores and in the size of the largest wheals as early as day 1." | 5.12 | Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. ( Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2007) |
| "The effect of 5 mg desloratadine for 4 days was tested with ice-cubes before and after 4 days of treatment in 12 patients with cold urticaria." | 5.11 | Inhibition of cold urticaria by desloratadine. ( Juhlin, L, 2004) |
| "Cetirizine and desloratadine are antihistamines active in the treatment of symptoms associated with seasonal allergic rhinitis and chronic urticaria." | 5.11 | Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours. ( Frossard, N; Melac, M; Pauli, G; Purohit, A, 2004) |
| " Both desloratadine alone and desloratadine plus montelukast administered once daily yielded improvements with respect to the baseline assessment as regards pruritus, number of separate episodes, size and number of weals, visual analogue score and patients' quality of life and with respect to the placebo group both in the active treatment period and in the run-out period." | 5.11 | Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. ( Colanardi, MC; Ferrannini, A; Nettis, E; Paradiso, MT, 2004) |
| "Levocetirizine is the active enantiomer of cetirizine, a potent drug with little metabolism widely used for allergic rhinitis and urticaria." | 5.10 | A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. ( DeVos, C; Grant, JA; Moulaert, B; Riethuisen, JM, 2002) |
| "Compared with placebo, desloratadine significantly improved the total CIU symptom score as well as pruritus, the number of hives, and the size of the largest hive." | 5.10 | Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. ( Bernstein, D; Finn, A; Guerrero, R; Monroe, E; Patel, P; Ratner, P, 2003) |
| "Olopatadine hydrochloride is one of the second-generation nonsedating antihistamines that are used for treating allergic disorders such as urticaria, rhinitis, and atopic dermatitis." | 5.10 | Rapid effects of olopatadine hydrochloride on the histamine-induced skin responses. ( Furue, M; Koga, T; Morita, K; Moroi, Y; Urabe, K, 2002) |
| "Desloratadine was superior to placebo in controlling pruritus and total symptoms after the first dose and maintained this superiority to the end of the study." | 5.09 | Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. ( Bronsky, E; Gauger, A; Hein, R; Miller, B; Ring, J, 2001) |
| "To compare the clinical efficacy and safety of mizolastine with loratadine and placebo in patients with chronic idiopathic urticaria (CIU)." | 5.09 | Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. ( Dubertret, L; Murrieta Aguttes, M; Tonet, J, 1999) |
| "The urticarial reaction was reduced substantially under treatment with 10 mg loratadine over a period of 7 days." | 5.07 | Evaluation of the efficacy of H1 blockers by noninvasive measurement techniques. ( Altmeyer, P; Auer, T; Dirschka, T; el-Gammal, S; Hoffmann, K; Stücker, M, 1994) |
| "To analyze the efficacy and safety of Tripterygium Glycosides Tablets combined with desloratadine as well as desloratadine alone in the treatment of chronic urticaria by Meta-analysis,in order to provide evidence-based reference for clinical treatment." | 5.01 | [Meta-analysis of efficacy and safety of Tripterygium Glycosides Tablets combined with desloratadine in treatment of chronic urticarial]. ( Pang, GX; Qiu, XJ; Shi, YS; Wang, QM, 2019) |
| "Bilastine is an orally administered, second-generation antihistamine used in the symptomatic treatment of seasonal or perennial allergic rhinoconjunctivitis and urticaria." | 4.88 | Bilastine: in allergic rhinitis and urticaria. ( Carter, NJ, 2012) |
| " Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0." | 4.86 | Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010) |
| "Desloratadine is approved for the treatment of symptoms associated with seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), and chronic idiopathic urticaria (CIU) in patients aged > or =12 years." | 4.82 | Desloratadine: a nonsedating antihistamine. ( Kockler, DR; Limon, L, 2003) |
| "Levocetirizine and desloratadine are newer antihistamines indicated for the treatment of allergic rhinitis and chronic idiopathic urticaria." | 4.82 | A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis. ( Canonica, GW; Passalacqua, G, 2005) |
| "The second-generation H1-receptor antagonists terfenadine, astemizole, loratadine, and cetirizine are important first-line drugs for the relief of symptoms in patients with allergic rhinoconjunctivitis or chronic urticaria and may eventually supplant the potentially sedating first-generation H1-receptor antagonists in the treatment of these disorders." | 4.78 | Recent advances in H1-receptor antagonist treatment. ( Simons, FE, 1990) |
| "To demonstrate the treatment outcomes and dose reduction in desloratadine assessed using the urticarial activity score over 7 consecutive days." | 3.88 | The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria. ( Chaowattanapanit, S; Choonhakarn, C; Julanon, N, 2018) |
| "H1-receptor inhibiting drugs, namely loratadine and cetirizine, were frequently used in treatment of chronic urticaria." | 3.80 | Effects of loratadine and cetirizine on serum levels of neuropeptides in patients with chronic urticaria. ( Başak, PY; Buyukbayram, HI; Erturan, I; Kazanoglu, OO; Vural, H, 2014) |
| " Desloratadine, a non-sedating, second-generation H(1)-receptor antagonist, is an effective and well-tolerated treatment for chronic idiopathic urticaria (CIU)." | 3.75 | Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. ( Augustin, M; Ehrle, S, 2009) |
| "The effects of one week's daily treatment with dexchlorpheniramine (3 + 3 mg x 2) and loratadine (10 mg x 2) on the cutaneous reactions to putative mediators of urticarial reactions were studied in healthy subjects and in patients with chronic urticaria." | 3.68 | Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects. ( Juhlin, L; Pihl-Lundin, I, 1992) |
| "Cold urticaria is a rare but severe and potentially lethal condition." | 2.77 | Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H(1) -antihistamine dose escalation. ( Church, MK; Magerl, M; Martus, P; Maurer, M; Pisarevskaja, D; Staubach, P, 2012) |
| "Levocetirizine was significantly more potent than desloratadine." | 2.73 | Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. ( Frossard, N; Pauli, G; Purohit, A; Strolin-Benedetti, M, 2008) |
| " The efficiency and side-effect were evaluated at the end of treatment." | 2.73 | Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria. ( Abdalla, AN; Khalaf, AT; Liu, XM; Sheng, WX; Tan, JQ, 2008) |
| "Treatment with desloratadine caused a relevant reduction of ROS levels and SOD activity (P<0." | 2.72 | Influence of desloratadine on oxidative stress markers in patients with chronic idiopathic urticaria. ( Amoruso, A; Cassano, N; D'Argento, V; Filieri, M; Filotico, R; Raho, G; Vena, GA, 2006) |
| "Fexofenadine is a potent suppressor of the histamine-induced wheal and flare response in healthy Japanese volunteers." | 2.71 | Suppression of the histamine-induced wheal and flare response by fexofenadine HCl 60 mg twice daily, loratadine 10 mg once daily and placebo in healthy Japanese volunteers. ( Boyle, J; Hindmarch, I; Johnsen, S; Meadows, R; Ridout, F, 2005) |
| "To compare the activity of antihistamines by the index of area under dose-response curve (AUDRC) obtained from histamine-induced wheal and flare reactions." | 2.71 | [Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin]. ( Wang, RQ; Zhang, HY, 2004) |
| " Desloratadine, an oral non-sedating antihistamine, has been shown in multiple studies to be safe and effective in relieving the symptoms of AR and chronic idiopathic urticaria (CIU) in adults and adolescents." | 2.71 | Safety of desloratadine syrup in children. ( Bloom, M; Herron, J; Staudinger, H, 2004) |
| "Levocetirizine (5 mg) is a potent inhibitor of the effects of histamine in human skin with an efficacy that exceeded that of loratadine (10 mg) when single doses of the drugs were administered 4 h before the test." | 2.70 | Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. ( Boutsiouki, P; Church, MK; Clough, GF, 2001) |
| "Ebastine was no better than placebo until 4 h, but was efficacious thereafter until 24 h." | 2.69 | A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. ( Danielson, L; DeVos, C; Grant, JA; Rihoux, JP, 1999) |
| "Cetirizine was found to be superior to acrivastine and loratadine for the suppression of wheal and flare responses at 240, 360 min and 24 h (P < 0." | 2.69 | Effects of acrivastine, loratadine and cetirizine on histamine-induced wheal and flare responses. ( Altintaş, L; Apaydýn, R; Bayramgürler, D; Bilen, N; Dökmeci, S; Sal, G; Utkan, T, 1999) |
| "Loratadine was well tolerated in this small, selected group of children aged 2 to 5 years at a dose providing exposure similar to that with the adult dose (ie, 10 mg once daily)." | 2.69 | The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. ( Affrime, MB; Banfield, C; Herron, JM; Lorber, R; Padhi, D; Salmun, LM, 2000) |
| "Although acute urticaria is common, its eliciting factors, clinical course and therapeutic responsiveness have not been intensively investigated." | 2.68 | Acute urticaria: clinical aspects and therapeutic responsiveness. ( Henz, BM; Iffländer, J; Semmler, C; Zuberbier, T, 1996) |
| "Loratadine was safe and well tolerated with sedation and dry mouth similar to placebo and significantly less than hydroxyzine." | 2.67 | Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. ( Bernstein, DI; Cuss, F; Danzig, MR; Fox, RW; Garvin, PR; Grabiec, SV; Honsinger, RW; Kalivas, JT; Katz, HI; Monroe, EW, 1992) |
| "Loratadine is a new selective peripheral histamine H1-receptor antagonist, that is orally effective, long-acting, and devoid of significant central and autonomic nervous system activity." | 2.67 | Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria. ( Belaich, S; Bruttmann, G; DeGreef, H; Lachapelle, JM; Paul, E; Pedrali, P; Tennstedt, D, 1990) |
| "Loratadine is a new, highly selective, non sedating, H 1-receptor antagonist, without central nervous system activity." | 2.67 | [Effectiveness of loratadine vs. placebo in the treatment of urticaria-angioedema syndrome in patients with food allergy]. ( Biasi, D; Corrocher, R; Cortina, P; Girelli, D; Pacor, ML, 1993) |
| " One hour prior to dosing and 1, 2, 3, 4, 6, 8, 12, 16, 24, 28, 32, 36, 40, and 48 hours after dosing, histamine and saline were injected intradermally into opposite arms." | 2.66 | Effects of loratadine (SCH 29851) in suppression of histamine-induced skin wheals. ( Dyer, JG; Gural, R; Kassem, N; Robillard, N; Roman, I, 1988) |
| "Guidelines for the treatment of urticaria issued by Polish and international expert bodies were analyzed, along with the SPCs." | 2.49 | [Pharmacotherapy of urticaria--an analysis of the discrepancies between guidelines of expert bodies, registration documents and evidence for the effectiveness of drugs]. ( Plichta, D; Spiewak, R, 2013) |
| " No major cytochrome P450 inhibition has been reported with desloratadine, fexofenadine and levocetirizine, and the bioavailability of desloratadine is minimally affected by drugs interfering with transporter molecules." | 2.44 | Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. ( Devillier, P; Faisy, C; Roche, N, 2008) |
| "Desloratadine displays linear pharmacokinetics after oral administration." | 2.44 | Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. ( DuBuske, L, 2007) |
| " Although first-generation antihistamines can cause sedation and cognitive impairment, second-generation antihistamines are relatively non-sedating and free of such adverse events owing to their comparative inability to penetrate the blood-brain barrier." | 2.43 | The safety and efficacy of desloratadine for the management of allergic disease. ( Berger, WE, 2005) |
| "Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist." | 2.43 | Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. ( DuBuske, LM, 2005) |
| "Desloratadine is a once-daily oral antihistamine with a favourable sedation profile that is approved for the treatment of AR and CIU." | 2.43 | Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety. ( Gupta, S; Kantesaria, B; Khalilieh, S; Kim, K; Lorber, R; Lutsky, B; Manitpisitkul, P; Prenner, B; Wang, Z, 2006) |
| "Desloratadine is a novel, potent H1-receptor antagonist with additional inhibitory effects on inflammatory mediators such as cytokines and adhesion molecules." | 2.41 | Desloratadine in the treatment of chronic idiopathic urticaria. ( Gauger, A; Hein, R; Ring, J, 2001) |
| "Desloratadine is a new non-sedating H1-receptor agonist." | 2.41 | Desloratidine for the treatment of chronic urticaria. ( Monroe, EW, 2002) |
| "Loratadine is an especially effective second-generation H1-receptor antagonist and is comparable to many of the other second-generation antihistamines." | 2.38 | Loratadine. A review of recent findings in pharmacology, pharmacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine. ( Danzig, MR; Roman, IJ, 1993) |
| "Loratadine is a long acting antihistamine which has a high selectivity for peripheral histamine H1-receptors and lacks the central nervous system depressant effects often associated with some of the older antihistamines." | 2.38 | Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. ( Clissold, SP; Goa, KL; Sorkin, EM, 1989) |
| " In cases of failure, treatment was switched to omalizumab at doses of < 300 mg/month with incremental dosage increases as necessary (monthly dose range, 150-600 mg/month)." | 1.51 | Real-life experience in the treatment of solar urticaria: retrospective cohort study. ( Enk, CD; Hodak, E; Lapidoth, M; Levi, A; Mazor, S; Snast, I; Uvaidov, V, 2019) |
| " Patients could be categorized into four groups based on the results of ASST and SPT to HDM and patients with positive ASST and positive SPT to HDM had the highest disease activity scores, experienced higher frequencies of angioedema, diseases duration, and required higher dosage of loratadine every month, compared with other subgroups (P<0." | 1.39 | Evaluation of autologous serum skin test and skin prick test reactivity to house dust mite in patients with chronic spontaneous urticaria. ( Chen, W; Hao, F; Song, Z; Zhai, Z; Zhong, H; Zhou, Z, 2013) |
| " It is concluded that estimating in vivo receptor occupancy, which takes into account both the affinity of the drug for the receptor and its free plasma concentration, is a far better predictor for human pharmacodynamics and hence antihistamine potency, than considering in vitro affinity and plasmatic half-life only." | 1.33 | Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. ( Baltes, E; Benedetti, MS; Chatelain, P; Gillard, M, 2005) |
| "Desloratadine is a new, selective, H(1)-receptor antagonist that also has anti-inflammatory activity." | 1.31 | Desloratadine: A new, nonsedating, oral antihistamine. ( Geha, RS; Meltzer, EO, 2001) |
| "Desloratadine was well tolerated in clinical trials and had an adverse event profile similar to that of placebo in patients with SAR (with or without asthma) or CIU." | 1.31 | Desloratadine. ( Jarvis, B; McClellan, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (2.54) | 18.7374 |
| 1990's | 20 (16.95) | 18.2507 |
| 2000's | 56 (47.46) | 29.6817 |
| 2010's | 38 (32.20) | 24.3611 |
| 2020's | 1 (0.85) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J | 5 |
| Chen, W | 5 |
| Peng, C | 2 |
| Zhu, W | 4 |
| Liu, Z | 4 |
| Zhang, W | 2 |
| Su, J | 4 |
| Chen, X | 7 |
| Shi, YS | 1 |
| Wang, QM | 1 |
| Qiu, XJ | 1 |
| Pang, GX | 1 |
| Maouia, A | 1 |
| Youssef, M | 1 |
| Leban, N | 1 |
| Ben Chibani, J | 1 |
| Helal, AN | 1 |
| Kassab, A | 1 |
| Zheng, D | 1 |
| Yang, X | 1 |
| Burguete-Cabanas, MT | 1 |
| Fajardo-Ramirez, OR | 1 |
| Yesaki, R | 1 |
| Estrada-Maganas, R | 1 |
| Salazar-Meza, S | 1 |
| Rios-Chavez, O | 1 |
| Meester, I | 1 |
| Salas-Alanis, JC | 1 |
| Fukumoto, T | 1 |
| Ogura, K | 1 |
| Fukunaga, A | 1 |
| Nishigori, C | 1 |
| Napolitano, M | 1 |
| Gallo, R | 1 |
| Donnarumma, M | 1 |
| Patruno, C | 1 |
| Choonhakarn, C | 1 |
| Chaowattanapanit, S | 1 |
| Julanon, N | 1 |
| Yan, J | 1 |
| Li, Q | 1 |
| Luo, Y | 1 |
| Yan, S | 4 |
| He, Y | 4 |
| Wang, J | 1 |
| Zhao, Y | 3 |
| Yan, X | 1 |
| Meijer, JM | 1 |
| van Dalen, T | 1 |
| van der Wal, B | 1 |
| Snast, I | 1 |
| Lapidoth, M | 1 |
| Uvaidov, V | 1 |
| Enk, CD | 2 |
| Mazor, S | 1 |
| Hodak, E | 1 |
| Levi, A | 2 |
| Authried, G | 2 |
| Bracher, L | 2 |
| Bygum, A | 1 |
| Bulca, S | 1 |
| Bayramgürler, D | 2 |
| Odyakmaz Demirsoy, E | 1 |
| Yavuz, M | 1 |
| Sikar Aktürk, A | 1 |
| Bilen, N | 2 |
| Kıran, R | 1 |
| Song, Z | 1 |
| Zhai, Z | 1 |
| Zhong, H | 1 |
| Zhou, Z | 1 |
| Hao, F | 1 |
| Leiva-Salinas, M | 1 |
| Francés, L | 1 |
| Marin-Cabanas, I | 1 |
| Arribas Granados, MP | 1 |
| Silvestre, JF | 1 |
| Plichta, D | 1 |
| Spiewak, R | 1 |
| Başak, PY | 1 |
| Vural, H | 1 |
| Kazanoglu, OO | 1 |
| Erturan, I | 1 |
| Buyukbayram, HI | 1 |
| Sharma, M | 1 |
| Bennett, C | 1 |
| Cohen, SN | 1 |
| Carter, B | 1 |
| Guo, A | 3 |
| Zhang, C | 2 |
| Wen, S | 2 |
| Chen, M | 3 |
| Zhang, J | 3 |
| Zhou, H | 2 |
| Zeng, W | 2 |
| Potter, P | 1 |
| Mitha, E | 1 |
| Barkai, L | 1 |
| Mezei, G | 1 |
| Santamaría, E | 1 |
| Izquierdo, I | 1 |
| Maurer, M | 7 |
| Svendsen, MT | 1 |
| Eker, E | 1 |
| Raison-Peyron, N | 1 |
| Reymann, V | 1 |
| Bessis, D | 1 |
| Bin, L | 1 |
| Yi, M | 1 |
| Leung, DY | 1 |
| Potter, PC | 1 |
| Kapp, A | 1 |
| Guillet, G | 1 |
| Jian, AM | 1 |
| Hauptmann, P | 1 |
| Finlay, AY | 1 |
| Grob, JJ | 3 |
| Auquier, P | 3 |
| Dreyfus, I | 3 |
| Ortonne, JP | 3 |
| Siebenhaar, F | 1 |
| Degener, F | 1 |
| Zuberbier, T | 3 |
| Martus, P | 3 |
| Inomata, N | 1 |
| Tatewaki, S | 1 |
| Ikezawa, Z | 1 |
| Augustin, M | 1 |
| Ehrle, S | 1 |
| dos Santos, RV | 1 |
| Magerl, M | 2 |
| Mlynek, A | 1 |
| Lima, HC | 1 |
| Kiyici, S | 1 |
| Gul, OO | 1 |
| Baskan, EB | 1 |
| Hacioglu, S | 1 |
| Budak, F | 1 |
| Erturk, E | 1 |
| Imamoglu, S | 1 |
| Bachert, C | 2 |
| Hornby, SA | 1 |
| Staevska, M | 1 |
| Popov, TA | 2 |
| Kralimarkova, T | 1 |
| Lazarova, C | 1 |
| Kraeva, S | 1 |
| Popova, D | 1 |
| Church, DS | 1 |
| Dimitrov, V | 2 |
| Church, MK | 5 |
| Bérard, F | 1 |
| Boulinguez, S | 1 |
| Hong, JB | 2 |
| Lee, HC | 2 |
| Hu, FC | 1 |
| Chu, CY | 2 |
| Yavuz, ST | 1 |
| Sahiner, UM | 1 |
| Tuncer, A | 1 |
| Sackesen, C | 1 |
| Bobadilla-González, P | 1 |
| Pérez-Rangel, I | 1 |
| Cámara-Hijón, C | 1 |
| García-Menaya, JM | 1 |
| Sánchez-Vega, S | 1 |
| Cimbollek, S | 1 |
| Ortega Camarero, M | 1 |
| Avila, R | 1 |
| Quiralte, J | 1 |
| Prados, M | 1 |
| Pisarevskaja, D | 1 |
| Staubach, P | 1 |
| Carter, NJ | 1 |
| Weller, K | 1 |
| Ardelean, E | 1 |
| Scholz, E | 1 |
| Morita, K | 1 |
| Koga, T | 1 |
| Moroi, Y | 1 |
| Urabe, K | 1 |
| Furue, M | 1 |
| Monroe, EW | 4 |
| Limon, L | 1 |
| Kockler, DR | 1 |
| Sabbah, A | 1 |
| Grattan, CE | 1 |
| Dawn, G | 1 |
| Gibbs, S | 1 |
| Francis, DM | 1 |
| Monroe, E | 1 |
| Finn, A | 1 |
| Patel, P | 1 |
| Guerrero, R | 1 |
| Ratner, P | 1 |
| Bernstein, D | 1 |
| Nettis, E | 3 |
| Pannofino, A | 1 |
| Cavallo, E | 1 |
| Ferrannini, A | 3 |
| Tursi, A | 1 |
| Purohit, A | 3 |
| Melac, M | 2 |
| Pauli, G | 3 |
| Frossard, N | 3 |
| Juhlin, L | 2 |
| Roongapinun, S | 1 |
| Wajajamreon, S | 1 |
| Fooanant, S | 1 |
| Colanardi, MC | 2 |
| Paradiso, MT | 1 |
| Di Lorenzo, G | 1 |
| Pacor, ML | 2 |
| Mansueto, P | 1 |
| Esposito Pellitteri, M | 1 |
| Lo Bianco, C | 1 |
| Ditta, V | 1 |
| Martinelli, N | 1 |
| Rini, GB | 1 |
| Wang, RQ | 1 |
| Zhang, HY | 1 |
| Bloom, M | 1 |
| Staudinger, H | 1 |
| Herron, J | 1 |
| Rottem, M | 1 |
| Elbirt, D | 1 |
| Sthoeger, Z | 1 |
| Passalacqua, G | 1 |
| Canonica, GW | 1 |
| Boyle, J | 1 |
| Ridout, F | 1 |
| Meadows, R | 1 |
| Johnsen, S | 1 |
| Hindmarch, I | 1 |
| DuBuske, LM | 1 |
| Gillard, M | 1 |
| Benedetti, MS | 1 |
| Chatelain, P | 1 |
| Baltes, E | 1 |
| Berger, WE | 1 |
| Saray, Y | 1 |
| Seçkin, D | 1 |
| Prenner, B | 1 |
| Kim, K | 1 |
| Gupta, S | 1 |
| Khalilieh, S | 1 |
| Kantesaria, B | 1 |
| Manitpisitkul, P | 1 |
| Lorber, R | 2 |
| Wang, Z | 1 |
| Lutsky, B | 1 |
| Lachapelle, JM | 2 |
| Decroix, J | 1 |
| Henrijean, A | 1 |
| Roquet-Gravy, PP | 1 |
| De Swerdt, A | 1 |
| Boonen, H | 1 |
| Lecuyer, M | 1 |
| Suys, E | 1 |
| Speelman, G | 1 |
| Vastesaeger, N | 1 |
| Kupczyk, M | 1 |
| Kupryś, I | 1 |
| Górski, P | 1 |
| Kuna, P | 1 |
| Cassano, N | 1 |
| Raho, G | 1 |
| Filieri, M | 1 |
| D'Argento, V | 1 |
| Amoruso, A | 1 |
| Filotico, R | 1 |
| Vena, GA | 1 |
| Dumitrascu, D | 1 |
| Bachvarova, A | 1 |
| Bocsan, C | 1 |
| Soccio, AL | 1 |
| Vacca, A | 1 |
| Kłos, K | 2 |
| Kruszewski, J | 2 |
| Kruszewski, R | 1 |
| Sułek, K | 2 |
| DuBuske, L | 1 |
| Strolin-Benedetti, M | 1 |
| Khalaf, AT | 1 |
| Liu, XM | 1 |
| Sheng, WX | 1 |
| Tan, JQ | 1 |
| Abdalla, AN | 1 |
| Engin, B | 1 |
| Ozdemir, M | 1 |
| Devillier, P | 1 |
| Roche, N | 1 |
| Faisy, C | 1 |
| Hoffmann, K | 1 |
| Auer, T | 1 |
| Stücker, M | 1 |
| Dirschka, T | 1 |
| el-Gammal, S | 1 |
| Altmeyer, P | 1 |
| Goldsmith, P | 1 |
| Dowd, PM | 1 |
| Roman, IJ | 1 |
| Danzig, MR | 2 |
| Biasi, D | 1 |
| Girelli, D | 1 |
| Cortina, P | 1 |
| Corrocher, R | 1 |
| Iffländer, J | 1 |
| Semmler, C | 1 |
| Henz, BM | 1 |
| Rihoux, JP | 2 |
| Donnelly, F | 1 |
| Burtin, B | 1 |
| Aelony, Y | 1 |
| Dubertret, L | 1 |
| Murrieta Aguttes, M | 1 |
| Tonet, J | 1 |
| Grant, JA | 2 |
| Danielson, L | 1 |
| DeVos, C | 2 |
| Apaydýn, R | 1 |
| Altintaş, L | 1 |
| Sal, G | 1 |
| Dökmeci, S | 1 |
| Utkan, T | 1 |
| de la Serna Higuera, C | 1 |
| Salmun, LM | 1 |
| Herron, JM | 1 |
| Banfield, C | 1 |
| Padhi, D | 1 |
| Affrime, MB | 1 |
| Simons, FE | 3 |
| Johnston, L | 1 |
| Simons, KJ | 2 |
| Ring, J | 2 |
| Hein, R | 2 |
| Gauger, A | 2 |
| Bronsky, E | 1 |
| Miller, B | 1 |
| Geha, RS | 1 |
| Meltzer, EO | 1 |
| McClellan, K | 1 |
| Jarvis, B | 1 |
| Clough, GF | 1 |
| Boutsiouki, P | 1 |
| Riethuisen, JM | 1 |
| Moulaert, B | 1 |
| Pihl-Lundin, I | 1 |
| Bernstein, DI | 2 |
| Fox, RW | 2 |
| Grabiec, SV | 1 |
| Honsinger, RW | 1 |
| Kalivas, JT | 1 |
| Katz, HI | 1 |
| Cuss, F | 1 |
| Garvin, PR | 1 |
| Abu Shareeah, AM | 1 |
| Soter, NA | 1 |
| Belaich, S | 1 |
| Bruttmann, G | 1 |
| DeGreef, H | 1 |
| Paul, E | 1 |
| Pedrali, P | 1 |
| Tennstedt, D | 1 |
| McMillan, JL | 1 |
| Clissold, SP | 1 |
| Sorkin, EM | 1 |
| Goa, KL | 1 |
| Green, AW | 1 |
| Izuno, GT | 1 |
| Pleskow, WW | 1 |
| Willis, I | 1 |
| Brigante, JR | 1 |
| Kassem, N | 1 |
| Roman, I | 1 |
| Gural, R | 1 |
| Dyer, JG | 1 |
| Robillard, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "A Pilot, Multicenter, Double-blind Randomized Study for Comparison of Aerius® Continuous Treatment Versus Aerius® PRN Regimen on Chronic Idiopathic Urticaria Patient Quality of Life"[NCT00783354] | Phase 4 | 129 participants (Actual) | Interventional | 2003-04-01 | Completed | ||
| Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial[NCT02646020] | Phase 2 | 138 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Efficacy and Safety of 20 mg Levocetirizine and 15 mg Levocetirizine + 50 mg Bed-Time Hydroxyzine in Severe Chronic Urticaria in Adults: a Pilot, Randomized, Double-blind, Cross-over and Parallel, Active-controlled, Single-centre Study[NCT01250652] | Phase 4 | 24 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Quality of Life in Patients With Allergic Rhinitis: a Clinical Trial Comparing the Use of Bilastine Versus Loratadine[NCT02513290] | Phase 4 | 73 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| An Exploratory Phase III, Randomised, Double-blind, Therapeutic Single Dose-related Effect, Parallel Group Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)[NCT00598611] | Phase 3 | 29 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| A Placebo Controlled Trial to Evaluate The Effects of Levocetirizine on Nasal Allergen Challenge And Adenosine Monophosphate Challenge In Patients With Intermittent and Persistent Allergic Rhinitis[NCT00679250] | Phase 4 | 25 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
24 reviews available for loratadine and Urticaria
| Article | Year |
|---|---|
[Meta-analysis of efficacy and safety of Tripterygium Glycosides Tablets combined with desloratadine in treatment of chronic urticarial].
Topics: Drug Therapy, Combination; Drugs, Chinese Herbal; Glycosides; Humans; Loratadine; Quality of Life; R | 2019 |
[Pharmacotherapy of urticaria--an analysis of the discrepancies between guidelines of expert bodies, registration documents and evidence for the effectiveness of drugs].
Topics: Administration, Oral; Administration, Topical; Anti-Allergic Agents; Benzimidazoles; Cetirizine; Glu | 2013 |
H1-antihistamines for chronic spontaneous urticaria.
Topics: Cetirizine; Cyproheptadine; Histamine H1 Antagonists; Humans; Hydroxyzine; Loratadine; Randomized Co | 2014 |
Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.
Topics: Activities of Daily Living; Adult; Anti-Allergic Agents; Chronic Disease; Female; Germany; Histamine | 2010 |
[Diagnostic and physiopathological innovations related to chronic urticaria].
Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Autoantibodie | 2010 |
Bilastine: in allergic rhinitis and urticaria.
Topics: Area Under Curve; Benzimidazoles; Cetirizine; Histamine H1 Antagonists, Non-Sedating; Humans; Lorata | 2012 |
H(1)-antihistamines and urticaria: how can we predict the best drug for our patient?
Topics: Anti-Allergic Agents; Cetirizine; Histamine; Histamine H1 Antagonists, Non-Sedating; Humans; Loratad | 2012 |
Therapeutic points of intervention and clinical implications: role of desloratadine.
Topics: Asthma; Clinical Trials as Topic; Drug Administration Schedule; Histamine H1 Antagonists; Humans; Lo | 2002 |
Desloratidine for the treatment of chronic urticaria.
Topics: Chronic Disease; Histamine H1 Antagonists; Humans; Loratadine; Urticaria | 2002 |
Desloratadine: a nonsedating antihistamine.
Topics: Adult; Area Under Curve; Child; Female; Half-Life; Histamine H1 Antagonists, Non-Sedating; Humans; L | 2003 |
[The place of new antihistamines in allergy management. Apropos of desloratadine].
Topics: Anti-Allergic Agents; Double-Blind Method; Half-Life; Histamine H1 Antagonists; Histamine Release; H | 2002 |
A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis.
Topics: Cetirizine; Histamine Antagonists; Humans; Loratadine; Nose; Piperazines; Quality of Life; Randomize | 2005 |
Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders.
Topics: Adult; Aged; Animals; Anti-Inflammatory Agents; Asthma; Child; Child, Preschool; Chronic Disease; Cl | 2005 |
The safety and efficacy of desloratadine for the management of allergic disease.
Topics: Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Product Surveillance, Postmarketing; Ran | 2005 |
Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety.
Topics: Administration, Oral; Age Factors; Dose-Response Relationship, Drug; Electrocardiography; Histamine | 2006 |
Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy.
Topics: Acetates; Adolescent; Adult; Child; Chronic Disease; Cyclopropanes; Drug Therapy, Combination; Hista | 2007 |
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.
Topics: Cetirizine; Drug Interactions; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Rhinitis, | 2008 |
The new H1 antihistamines. Treatment of urticaria and other clinical problems.
Topics: Astemizole; Cetirizine; Dermatitis, Atopic; Histamine H1 Antagonists; Humans; Loratadine; Terfenadin | 1993 |
Loratadine. A review of recent findings in pharmacology, pharmacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine.
Topics: Animals; Drug Therapy, Combination; Ephedrine; Humans; Loratadine; Rhinitis; Urticaria | 1993 |
Safety and efficacy of loratadine in urticaria.
Topics: Histamine H1 Antagonists; Humans; Loratadine; Urticaria | 1996 |
Desloratadine in the treatment of chronic idiopathic urticaria.
Topics: Cholinergic Antagonists; Chronic Disease; Cytokines; Histamine H1 Antagonists; Humans; Loratadine; S | 2001 |
Recent advances in H1-receptor antagonist treatment.
Topics: Astemizole; Benzhydryl Compounds; Benzimidazoles; Cetirizine; Cyproheptadine; Histamine H1 Antagonis | 1990 |
Three new non-sedative antihistamines: worth keeping an eye open for.
Topics: Cetirizine; Cyproheptadine; Histamine H1 Antagonists; Humans; Hydroxyzine; Loratadine; Rhinitis, All | 1990 |
Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
Topics: Animals; Common Cold; Cyproheptadine; Female; Humans; Loratadine; Male; Rhinitis, Allergic, Perennia | 1989 |
58 trials available for loratadine and Urticaria
| Article | Year |
|---|---|
Human H1 receptor (HRH1) gene polymorphism is associated with the severity of side effects after desloratadine treatment in Chinese patients with chronic spontaneous uticaria.
Topics: Adult; China; Chronic Disease; Drug-Related Side Effects and Adverse Reactions; Female; Histamine H1 | 2020 |
CRP relevance in clinical assessment of chronic spontaneous urticaria Tunisian patients.
Topics: Adult; Anti-Inflammatory Agents; Antioxidants; C-Reactive Protein; Catalase; Chronic Disease; Female | 2017 |
Clinical observation on the therapeutic effect of desloratadine citrate disodium in the treatment of chronic urticaria and changes in IL4, IL18, IL23 and IL-33 levels before and after treatment.
Topics: Adolescent; Adult; Chronic Disease; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Interleu | 2017 |
Effects of Desloratadine Citrate Disodium on Serum Immune Function Indices, Inflammatory Factors and Chemokines in Patients with Chronic Urticaria.
Topics: Administration, Oral; Adult; Biomarkers; Chemokine CCL5; Chemokines; China; Cholinergic Antagonists; | 2019 |
Comparison of effects of 5 and 10 mg oral desloratadine and levocetirizine on histamine-induced wheal and flare response in healthy volunteers.
Topics: Administration, Oral; Adult; Anti-Allergic Agents; Cetirizine; Cross-Over Studies; Double-Blind Meth | 2013 |
Association of FCER1A genetic polymorphisms with risk for chronic spontaneous urticaria and efficacy of nonsedating H1-antihistamines in Chinese patients.
Topics: Adult; Asian People; Benzimidazoles; China; Female; Genotyping Techniques; Histamine H1 Antagonists, | 2015 |
Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years.
Topics: Age Factors; Child; Child, Preschool; Chronic Disease; Cyproheptadine; Double-Blind Method; Female; | 2016 |
Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients.
Topics: Cetirizine; Chronic Disease; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Hu | 2009 |
How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life.
Topics: Adult; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Histamine H1 Anta | 2009 |
High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study.
Topics: Adolescent; Adult; Aged; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Histamin | 2009 |
Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines.
Topics: Adult; Allergens; Animals; Dermatophagoides pteronyssinus; Dibenzazepines; Double-Blind Method; Fema | 2009 |
Effect of levothyroxine treatment on clinical symptoms and serum cytokine levels in euthyroid patients with chronic idiopathic urticaria and thyroid autoimmunity.
Topics: Adolescent; Adult; Autoimmune Diseases; Chi-Square Distribution; Chronic Disease; Drug Combinations; | 2010 |
The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria.
Topics: Adult; Aged; Cetirizine; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Fem | 2010 |
A randomized, double-blind, active-controlled, parallel-group pilot study to compare the efficacy and sedative effects of desloratadine 5 mg with levocetirizine 5 mg in the treatment of chronic idiopathic urticaria.
Topics: Cetirizine; Chronic Disease; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Hu | 2010 |
Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H(1) -antihistamine dose escalation.
Topics: Adult; Aged; Cold Temperature; Dose-Response Relationship, Drug; Double-Blind Method; Histamine H1 A | 2012 |
Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study.
Topics: Adult; Aged; Double-Blind Method; Drug Administration Schedule; Germany; Histamine H1 Antagonists, N | 2013 |
Rapid effects of olopatadine hydrochloride on the histamine-induced skin responses.
Topics: Administration, Oral; Adult; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; | 2002 |
Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Child; Chronic Disease; Double-Blind Method; Drug Administr | 2003 |
Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria.
Topics: Acetates; Adult; Aged; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Histam | 2003 |
Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin.
Topics: Adolescent; Adult; Cetirizine; Circadian Rhythm; Cross-Over Studies; Double-Blind Method; Female; Hi | 2003 |
Inhibition of cold urticaria by desloratadine.
Topics: Adolescent; Adult; Aged; Cold Temperature; Female; Histamine H1 Antagonists, Non-Sedating; Humans; L | 2004 |
Comparative efficacy of wheal-and-flare suppression among various non-sedating antihistamines and the pharmacologic insights to their efficacy.
Topics: Adolescent; Adult; Cetirizine; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; M | 2004 |
Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours.
Topics: Adolescent; Adult; Anti-Allergic Agents; Area Under Curve; Cetirizine; Cross-Over Studies; Female; H | 2004 |
Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study.
Topics: Acetates; Administration, Oral; Adolescent; Adult; Aged; Chronic Disease; Cyclopropanes; Double-Blin | 2004 |
Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria.
Topics: Acetates; Adolescent; Adult; Aged; Chronic Disease; Cyclopropanes; Double-Blind Method; Female; Hist | 2004 |
[Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin].
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Area Under Curve; Benzimidazoles; Double-Blind Method | 2004 |
Safety of desloratadine syrup in children.
Topics: Acute Disease; Administration, Oral; Child; Child, Preschool; Double-Blind Method; Electrocardiograp | 2004 |
[Desloratadine for chronic idiopathic urticaria].
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Histamine H1 Antagonists, Non-Sedating; Hum | 2005 |
Suppression of the histamine-induced wheal and flare response by fexofenadine HCl 60 mg twice daily, loratadine 10 mg once daily and placebo in healthy Japanese volunteers.
Topics: Adult; Drug Therapy, Combination; Female; Histamine H1 Antagonists; Humans; Japan; Loratadine; Male; | 2005 |
Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria.
Topics: Administration, Oral; Adult; Belgium; Chronic Disease; Drug Administration Schedule; Female; Histami | 2006 |
The effect of montelukast (10mg daily) and loratadine (10mg daily) on wheal, flare and itching reactions in skin prick tests.
Topics: Acetates; Allergens; Antipruritics; Capsules; Codeine; Cross-Over Studies; Cyclopropanes; Double-Bli | 2007 |
Influence of desloratadine on oxidative stress markers in patients with chronic idiopathic urticaria.
Topics: Adult; Aged; Biomarkers; Chronic Disease; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Lo | 2006 |
A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo.
Topics: Adult; Cetirizine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Histam | 2006 |
Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study.
Topics: Acetates; Administration, Oral; Adolescent; Adult; Cyclopropanes; Double-Blind Method; Drug Therapy, | 2006 |
Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Histamine H1 | 2007 |
[The effect of 5-days of cetirizine, desloratadine, fexofenadine 120 and 180 mg, levocetirizine, loratadine treatment on the histamine-induced skin reaction and skin blood flow--a randomized, double-blind, placebo controlled trial].
Topics: Administration, Oral; Adult; Cetirizine; Double-Blind Method; Drug Administration Schedule; Histamin | 2006 |
[Inhibition of histamine-induced wheel after a recommended single dose administration of 10 mg cetirizine, 5 mg desloratadine, 120 i 180 mg fexofenadine, 5 mg levocetirizine and 10 mg loratadine--a randomized, double-blind, placebo controlled trial].
Topics: Administration, Oral; Adult; Cetirizine; Double-Blind Method; Histamine; Histamine H1 Antagonists, N | 2006 |
Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine.
Topics: Adolescent; Adult; Allergens; Cetirizine; Cholinergic Antagonists; Cross-Over Studies; Double-Blind | 2008 |
Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Child, Preschool; Chronic Disease; Dipyridamol | 2008 |
Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria.
Topics: Adolescent; Adult; Case-Control Studies; Dapsone; Female; Folic Acid Antagonists; Histamine H1 Antag | 2008 |
Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study.
Topics: Activities of Daily Living; Adult; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind M | 2008 |
Evaluation of the efficacy of H1 blockers by noninvasive measurement techniques.
Topics: Administration, Oral; Adult; Colorimetry; Drug Eruptions; Female; Humans; Hypersensitivity, Immediat | 1994 |
[Effectiveness of loratadine vs. placebo in the treatment of urticaria-angioedema syndrome in patients with food allergy].
Topics: Adult; Angioedema; Double-Blind Method; Drug Evaluation; Female; Food Hypersensitivity; Humans; Lora | 1993 |
Acute urticaria: clinical aspects and therapeutic responsiveness.
Topics: Acute Disease; Adolescent; Adult; Analgesics; Anti-Inflammatory Agents; Child; Child, Preschool; Dru | 1996 |
Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study.
Topics: Adult; Analysis of Variance; Appendicitis; Benzimidazoles; Chronic Disease; Double-Blind Method; Ele | 1999 |
A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects.
Topics: Adult; Butyrophenones; Cetirizine; Cross-Over Studies; Dibenzazepines; Double-Blind Method; Histamin | 1999 |
Effects of acrivastine, loratadine and cetirizine on histamine-induced wheal and flare responses.
Topics: Adult; Cetirizine; Cross-Over Studies; Female; Histamine; Histamine H1 Antagonists; Humans; Loratadi | 1999 |
The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years.
Topics: Anti-Allergic Agents; Biological Availability; Child, Preschool; Double-Blind Method; Drug Administr | 2000 |
Clinical pharmacology of the H1-receptor antagonists cetirizine and loratadine in children.
Topics: Anti-Allergic Agents; Cetirizine; Child; Cross-Over Studies; Double-Blind Method; Histamine H1 Antag | 2000 |
Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Cholinergic Antagonists; Chronic Disease; Dizziness; Double-Blind Method; D | 2001 |
Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin.
Topics: Anti-Allergic Agents; Cetirizine; Double-Blind Method; Histamine; Humans; Hypersensitivity, Immediat | 2001 |
A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.
Topics: Adult; Benzimidazoles; Butyrophenones; Cetirizine; Cross-Over Studies; Double-Blind Method; Histamin | 2002 |
Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Chronic Disease; Double-Blind Method; Humans; Hydroxyzine; Loratadine; Midd | 1992 |
Comparative efficacy of loratadine and terfenadine in the treatment of chronic idiopathic urticaria.
Topics: Adult; Chronic Disease; Cyproheptadine; Female; Histamine Antagonists; Humans; Loratadine; Male; Pru | 1992 |
Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Chronic Disease; Clinical Trials as Topic; Cyprohepta | 1990 |
A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects.
Topics: Adult; Astemizole; Benzhydryl Compounds; Benzimidazoles; Cetirizine; Chlorpheniramine; Cyproheptadin | 1990 |
Efficacy and safety of loratadine (10 mg once daily) in the management of idiopathic chronic urticaria.
Topics: Chronic Disease; Clinical Trials as Topic; Cyproheptadine; Double-Blind Method; Histamine H1 Antagon | 1988 |
Effects of loratadine (SCH 29851) in suppression of histamine-induced skin wheals.
Topics: Adolescent; Adult; Clinical Trials as Topic; Cyproheptadine; Dose-Response Relationship, Drug; Hista | 1988 |
36 other studies available for loratadine and Urticaria
| Article | Year |
|---|---|
Omalizumab for hypersensitive reaction to seminal plasma: A case report.
Topics: Adult; Anaphylaxis; Anti-Allergic Agents; Anti-Inflammatory Agents; Dexamethasone; Female; Humans; I | 2018 |
Aquagenic urticaria: Severe extra-cutaneous symptoms following cold water exposure.
Topics: Child; Chronic Inducible Urticaria; Cold Temperature; Dyspnea; Female; Histamine H1 Antagonists, Non | 2018 |
Salt-dependent aquagenic urticaria in children: Report of two cases.
Topics: Child; Chronic Inducible Urticaria; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadi | 2018 |
The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria.
Topics: Adult; Chronic Disease; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Maintena | 2018 |
[Association of CACNA1C gene genetic polymorphism with the susceptibility as well as prognosis for chronic spontaneous urticaria].
Topics: Calcium Channels, L-Type; Chronic Disease; Genetic Predisposition to Disease; Histamine H1 Antagonis | 2018 |
A Patient with Jaundice and Pruritus, Not the Usual Suspect?
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Glucocorticoids; Glutamyl Aminopeptidase; Hepatit | 2019 |
Real-life experience in the treatment of solar urticaria: retrospective cohort study.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Cetirizine; Child; Cohort Studies; Cyclopro | 2019 |
[Urticaria multiforme is a variation of urticaria, which imitates erythema multiforme].
Topics: Amoxicillin; Anti-Bacterial Agents; Diagnosis, Differential; Drug Eruptions; Erythema Multiforme; Hi | 2013 |
Evaluation of autologous serum skin test and skin prick test reactivity to house dust mite in patients with chronic spontaneous urticaria.
Topics: Adolescent; Adult; Age Factors; Aged; Animals; Anti-Allergic Agents; China; Chronic Disease; Female; | 2013 |
Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C.
Topics: Anti-Allergic Agents; Chronic Disease; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hist | 2015 |
Effects of loratadine and cetirizine on serum levels of neuropeptides in patients with chronic urticaria.
Topics: Adolescent; Adult; Calcitonin Gene-Related Peptide; Cetirizine; Chronic Disease; Female; Histamine H | 2014 |
Influence of component 5a receptor 1 (C5AR1) -1330T/G polymorphism on nonsedating H1-antihistamines therapy in Chinese patients with chronic spontaneous urticaria.
Topics: Adolescent; Adult; Aged; Asian People; Benzimidazoles; Case-Control Studies; China; Chronic Disease; | 2014 |
Treatment of solar urticaria using antihistamine and leukotriene receptor antagonist combinations tailored to disease severity.
Topics: Acetates; Adolescent; Adult; Cetirizine; Child; Child, Preschool; Cyclopropanes; Drug Therapy, Combi | 2015 |
Two Young Children with Rashes on Their Trunk and Extremities.
Topics: Diagnosis, Differential; Exanthema; Extremities; Histamine H1 Antagonists, Non-Sedating; Humans; Inf | 2015 |
Follicular Traction Urticaria: A New Form of Chronic Inducible Urticaria?
Topics: Administration, Oral; Biopsy; Chronic Disease; Drug Administration Schedule; Female; Hair Follicle; | 2017 |
Association of ORAI1 gene polymorphisms with chronic spontaneous urticaria and the efficacy of the nonsedating H1 antihistamine desloratadine.
Topics: Adult; Chronic Disease; Female; Genetic Association Studies; Genetic Predisposition to Disease; Geno | 2017 |
Multiple H1-antihistamine-induced urticaria.
Topics: Administration, Oral; Adult; Drug Eruptions; Female; Histamine; Histamine H1 Antagonists; Humans; Im | 2009 |
Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Chr | 2009 |
A common but interesting case history.
Topics: Adult; Antipruritics; Exercise; Humans; Loratadine; Male; Military Personnel; Naval Medicine; Prurit | 2009 |
Aquagenic urticaria in 2 adolescents.
Topics: Adolescent; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Male; Urticaria; Water | 2010 |
Positive basophil activation test result in a patient with acute urticaria induced by cetirizine and desloratadine.
Topics: Adult; Basophils; Cetirizine; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Ur | 2011 |
Chronic idiopathic urticaria in Taiwan: a clinical study of demographics, aggravating factors, laboratory findings, serum autoreactivity and treatment response.
Topics: Adolescent; Adult; Cetirizine; Chronic Disease; Female; Histamine H1 Antagonists; Humans; Loratadine | 2011 |
NSAID-sensitive antihistamine-induced urticaria/angioedema.
Topics: Adult; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Drug Hypersensitivity; Histamine H1 Anta | 2011 |
Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity.
Topics: Adult; Analysis of Variance; Anti-Inflammatory Agents; Basophils; Case-Control Studies; Chronic Dise | 2003 |
Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines.
Topics: Animals; Cetirizine; CHO Cells; Cricetinae; Cricetulus; Histamine H1 Antagonists; Humans; Loratadine | 2005 |
Angioedema and urticaria due to isotretinoin therapy.
Topics: Acne Vulgaris; Adolescent; Angioedema; Female; Humans; Isotretinoin; Loratadine; Urticaria | 2006 |
The clinical efficacy of H1 antagonists in urticaria and rhinitis.
Topics: Anti-Allergic Agents; Cetirizine; Histamine H1 Antagonists; Humans; Loratadine; Mathematical Computi | 1998 |
First-generation vs second-generation antihistamines.
Topics: Anti-Allergic Agents; Conflict of Interest; Diphenhydramine; Drug Industry; Histamine H1 Antagonists | 1998 |
[Angioedema and urticarial reaction induced by valsartan].
Topics: Angioedema; Anti-Allergic Agents; Antihypertensive Agents; Antipruritics; Drug Eruptions; Female; Fo | 2000 |
[Antihistaminics for urticaria. Scratching or yawning--alternatives of the past].
Topics: Dermatitis, Atopic; Histamine H1 Antagonists; Humans; Loratadine; Treatment Outcome; Urticaria; Yawn | 1999 |
Desloratadine: A new, nonsedating, oral antihistamine.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Drug Interactions; Histamine H1 Antagonist | 2001 |
Desloratadine.
Topics: Asthma; Clinical Trials as Topic; Drug Interactions; Histamine H1 Antagonists; Humans; Loratadine; R | 2001 |
[Urticaria. Finally undisturbed sleep].
Topics: Clinical Trials as Topic; Double-Blind Method; Histamine H1 Antagonists; Humans; Loratadine; Sleep; | 2001 |
Desloratadine (Clarinex).
Topics: Administration, Oral; Adolescent; Adult; Aged; Asthma; Controlled Clinical Trials as Topic; Disorder | 2002 |
Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects.
Topics: Adult; Aged; Chlorpheniramine; Chronic Disease; Eosinophils; Female; Histamine; Histamine H1 Antagon | 1992 |
Treatment of urticaria and angioedema: low-sedating H1-type antihistamines.
Topics: Angioedema; Astemizole; Benzhydryl Compounds; Benzimidazoles; Cetirizine; Cyproheptadine; Histamine | 1991 |